Daily Endocrinology Research Analysis
Three impactful endocrinology papers span mechanistic, translational, and care-delivery science. A Diabetes study uncovers adenylosuccinate (S-AMP) as a key mediator of imeglimin’s β-cell proliferative and antiapoptotic actions across multiple islet systems. A 3-year prospective extension of the 4T program shows durable HbA1c improvements in youth with type 1 diabetes using early CGM plus remote patient monitoring. A translational Obesity study suggests preconception GLP-1RA improves maternal li
Summary
Three impactful endocrinology papers span mechanistic, translational, and care-delivery science. A Diabetes study uncovers adenylosuccinate (S-AMP) as a key mediator of imeglimin’s β-cell proliferative and antiapoptotic actions across multiple islet systems. A 3-year prospective extension of the 4T program shows durable HbA1c improvements in youth with type 1 diabetes using early CGM plus remote patient monitoring. A translational Obesity study suggests preconception GLP-1RA improves maternal lipid metabolism via liver-secreted FGF21.
Research Themes
- β-cell metabolic resilience and therapeutic mechanisms
- Early CGM and remote monitoring to sustain glycemic outcomes in youth T1D
- GLP-1 biology, FGF21 signaling, and maternal-fetal lipid metabolism
Selected Articles
1. Adenylosuccinate Mediates Imeglimin-Induced Proliferative and Antiapoptotic Effects in β-Cells.
This mechanistic study shows that imeglimin elevates adenylosuccinate (S-AMP) in β-cells and that blocking its synthesis via ADSS inhibition attenuates imeglimin’s proliferative and antiapoptotic effects across mouse, human, porcine islets, and hPSC-derived β-cells. Findings position S-AMP as a metabolic mediator of imeglimin’s β-cell benefits.
Impact: Identifying S-AMP as a mediator links imeglimin to a concrete metabolic pathway, offering actionable targets for β-cell preservation strategies.
Clinical Implications: While preclinical, the S-AMP/ADSS axis could guide biomarker development and combination strategies to enhance β-cell survival in type 2 diabetes and islet transplantation.
Key Findings
- Imeglimin increases adenylosuccinate (S-AMP) and aspartate content in β-cells/islets.
- ADSS inhibition blunts imeglimin-induced β-cell proliferation and antiapoptotic effects.
- Effects are consistent across mouse, human, porcine islets, and hPSC-derived β-cells, indicating broad biological relevance.
Methodological Strengths
- Multi-system validation across species including human islets and hPSC-derived β-cells
- Causal probing of pathway via pharmacologic ADSS inhibition
Limitations
- Preclinical mechanistic work without in vivo clinical endpoints
- Quantitative dose–response and long-term in vivo β-cell functional outcomes not reported
Future Directions: Test S-AMP/ADSS modulation in vivo with metabolic phenotyping, evaluate translational biomarkers, and explore combination therapies that potentiate imeglimin’s β-cell effects.
Although imeglimin promotes β-cell proliferation and ameliorates β-cell apoptosis, the detailed metabolic changes induced by imeglimin in β-cells are unknown. Imeglimin increases adenylosuccinate (S-AMP), which is produced by adenylosuccinate synthase (ADSS) from inosine monophosphate and aspartate, and imeglimin also increases amino acid content, including aspartate, in mouse islets. Inhibition of S-AMP production by an ADSS inhibitor reduces the ability of imeglimin to increase β-cell proliferation and ameliorate β-cell apoptosis in mouse islets, human islets, porcine islets, and human pluripotent stem cell-derived β-cells. Imeglimin increases S-AMP to promote β-cell proliferation and ameliorate β-cell apoptosis.
2. Sustained HbA1c Improvements Over 36 Months in Youth in the Teamwork, Targets, Technology, and Tight Control (4T) Study.
Starting CGM within the first month of diagnosis and coupling it with intensive education and remote patient monitoring yielded a 1.2% adjusted HbA1c advantage at 3 years versus historical controls. Notably, 68% achieved HbA1c <7.5% and 37% achieved <7% at 3 years, supporting early technology-enabled care models.
Impact: Provides rare 3-year prospective evidence that early CGM plus structured RPM can durably improve glycemia in youth with T1D.
Clinical Implications: Supports early CGM initiation with intensive remote support in the first year post-diagnosis to achieve and sustain HbA1c targets; informs clinic resource allocation and payer policy.
Key Findings
- Adjusted HbA1c was 1.2% lower at 3 years compared with historical controls (95% CI 0.7–1.7%).
- At 3 years, 68% achieved HbA1c <7.5% and 37% achieved <7% versus 37% and 20% in controls.
- Intervention included CGM within 1 month of diagnosis, weekly RPM in year 1, then monthly RPM.
Methodological Strengths
- Prospective follow-up with predefined CGM-enabled care pathway
- Objective outcomes (HbA1c and CGM metrics) and 3-year duration
Limitations
- Nonrandomized design with historical controls may introduce selection and temporal biases
- Single-center study may limit generalizability
Future Directions: Randomized, multicenter trials comparing early CGM+RPM vs usual care, cost-effectiveness analyses, and identification of subgroups benefiting most.
CONTEXT: Youth with type 1 diabetes (T1D) struggle to meet and sustain hemoglobin A1c (HbA1c) targets. Youth enrolled in the Pilot 4T Study improved HbA1c by 0.5%, compared to historical controls at 1-year. OBJECTIVE: To assess 3 years of glycemic outcomes in the Pilot 4T Study. DESIGN: The Pilot 4T Extension cohort was prospectively followed to determine changes in HbA1c and continuous glucose monitoring (CGM) metrics over 3 years. SETTING: Stanford Medicine Children's Health Diabetes Clinic. PATIENTS OR OTHER PARTICIPANTS: Youth with T1D in the Pilot 4T Study enrolled in the extension phase. INTERVENTION: Youth started CGM in the first month of diabetes diagnosis, received intensified education and remote patient monitoring (RPM) weekly for the first year of diabetes diagnosis and monthly RPM in the extension phase. MAIN OUTCOME MEASURE: HbA1c and CGM metrics over the first 3 years of diagnosis. RESULTS: In the Pilot 4T cohort, 78.5% (n=102) of participants enrolled in the study extension phase and were followed through 3 years. The adjusted difference in HbA1c at 3 years was 1.2% (95% CI 0.7-1.7%) lower in the Pilot 4T cohort than in the Historical cohort. In the Pilot 4T cohort, 68% and 37% met the <7.5% and <7% HbA1c targets at 3 years, respectively, compared to 37% and 20% in the Historical cohort. CONCLUSIONS: Youth with T1D in the Pilot 4T extension phase sustained improvements in HbA1c over 3 years. Focusing resources on intensive management during the first year after T1D diagnosis may impact long-term glycemia.
3. Prepregnancy GLP-1RA use improves maternal lipid metabolism via liver-secreted FGF21 during pregnancy in HFD-fed dams.
A mixed human–animal study suggests that preconception GLP-1RA use lowers maternal triglycerides, gestational weight gain, and early-pregnancy MASLD likelihood, with rat data indicating hepatic FGF21 and downstream ERK/PPAR-γ and AMPK/SIRT1 pathway activation. Visceral adipose showed increased lipolysis and reduced lipogenesis signatures.
Impact: Links preconception GLP-1RA exposure to improved pregnancy lipid profiles and provides mechanistic support via hepatic FGF21 signaling.
Clinical Implications: For women with obesity planning pregnancy, optimizing metabolic status with GLP-1RA preconception may reduce gestational dyslipidemia and MASLD risk; safety and timing relative to conception must follow current guidelines.
Key Findings
- In women with obesity (n=42), preconception GLP-1RA use was associated with lower prepregnancy BMI, reduced gestational weight gain, reduced early MASLD proportion, and lower triglycerides.
- In HFD-fed pregnant rats, GLP-1RA increased plasma FGF21 and adiponectin and improved triglycerides in midgestation.
- Late-gestation liver showed increased FA oxidation/lipolysis gene expression, decreased lipogenesis genes, and activation of ERK/PPAR-γ and AMPK/SIRT1 pathways; visceral fat showed enhanced lipolysis and reduced lipogenesis with increased p-FGFR1.
Methodological Strengths
- Translational design combining human retrospective case-control with controlled animal experiments
- Pathway-level mechanistic readouts (FGF21, ERK/PPAR-γ, AMPK/SIRT1) and tissue-specific analyses
Limitations
- Small human sample size with retrospective design and potential confounding by weight loss behaviors
- Animal model translatability and periconception timing relative to human clinical practice require caution
Future Directions: Prospective trials evaluating preconception GLP-1RA timing, safety, and maternal–fetal metabolic outcomes, with biomarker studies of FGF21 signaling.
OBJECTIVE: Obesity in women of childbearing age disrupts lipid metabolism in pregnancy. This study aims to evaluate the impact of prepregnancy glucagon-like peptide-1 receptor agonist (GLP-1RA) use on lipid metabolism during pregnancy. METHODS: A retrospective case-control study with 42 participants was employed to analyze the impact of prepregnancy GLP-1RA use on lipid metabolism during pregnancy in women with obesity. An animal study involved 60 virgin female Sprague Dawley rats fed a normal diet or a high-fat diet (HFD) for 8 weeks, with the latter diet divided into HFD + saline, HFD + liraglutide, and HFD + semaglutide for 4 weeks. Rats were mated and then sacrificed on gestational day 21. RESULTS: Clinically, prepregnancy GLP-1RA use reduced prepregnancy BMI, gestational weight gain, ratio with first-trimester metabolic dysfunction-associated steatotic liver disease, and triglyceride levels during pregnancy. In animals, GLP-1RA improved plasma fibroblast growth factor 21 (FGF21), adiponectin, triglyceride levels, and leptin in midgestation. During late gestation, compared with the HFD group, the GLP-1RA groups exhibited improved liver lipid deposition, increased fatty acid oxidation and lipolysis genes, decreased lipogenesis genes, and increased extracellular signal-regulated kinase (ERK)/peroxisome proliferator-activated receptor γ (PPAR-γ) and AMP-activated protein kinase (AMPK)/NAD-dependent protein deacetylase sirtuin-1 (SIRT1) pathways in liver; in the visceral adipose, the GLP-1RA groups showed increased lipolysis genes, decreased lipogenesis genes, and increased phosphorylated to total fibroblast growth factor receptor 1 (FGFR1) with activated ERK/PPAR-γ pathways. CONCLUSIONS: Prepregnancy GLP-1RA use improves maternal lipid metabolism during pregnancy, potentially involving elevated liver-secreted FGF21. This study offers a new strategy for treating lipid metabolic disorders in pregnancy.